Clinical trial
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
NCT00308165 · Jeffrey N. Bruce, Other · Completed
Key facts
| NCT number | NCT00308165 |
|---|---|
| Title | Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors |
| Official title | A Phase I Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors |
| Lead sponsor | Jeffrey N. Bruce, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain Neoplasms, Primary Malignant |
| Intervention type | Drug, Procedure |
| Interventions | Convection-Enhanced Delivery, Topotecan |
| Enrollment | 16 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2015 |
| Completion | Jan 1, 2016 |
| First posted | Mar 29, 2006 |
| Last update posted | Jun 27, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: